Alpha-linolenic acid metabolism pathway (ALA metabolism)

The alpha-linolenic acid metabolism pathway encompasses all biochemical reactions converting dietary alpha-linolenic acid—a plant-derived essential omega‑3 fatty acid—into longer-chain polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Humans cannot synthesize ALA de novo and must obtain it from dietary sources like flaxseed oil, chia seeds, hempseed oil, rapeseed oil, soybeans, and leafy greens. Once ingested, ALA undergoes alternating steps of desaturation and elongation primarily in the endoplasmic reticulum before final beta oxidation steps occur in peroxisomes. Key enzymes include delta‑6 desaturase and delta‑5 desaturase. The resulting long-chain n−3 PUFAs play important roles in reducing inflammation and lowering risks associated with chronic diseases such as cardiovascular disease and arthritis[1][2][5]. In summary: The "alpha-linolenic acid metabolism pathway" is not itself a therapeutic target but rather describes an essential lipid metabolic process involving multiple enzymes that could individually be considered drug targets.[1][2]

Other names

ALA metabolismOmega-3 fatty acid biosynthesisn-3 PUFA biosynthetic pathway

Not applicable for the entire pathway. Drugs/supplements may act by providing substrates (e.g., ALA oil supplementation) or by modulating the activity of enzymes within the pathway (e.g., inhibition of delta-6 desaturase).